Neurogene Operating Cycle from 2010 to 2026
| NGNE Stock | 17.38 0.38 2.24% |
Operating Cycle | First Reported 2010-12-31 | Previous Quarter 230.13 | Current Value 241.63 | Quarterly Volatility 108.76497978 |
Check Neurogene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurogene's main balance sheet or income statement drivers, such as Depreciation And Amortization of 3.9 M, Other Operating Expenses of 100.9 M or Research Development of 73.6 M, as well as many indicators such as Price To Sales Ratio of 410, Dividend Yield of 0.0 or PTB Ratio of 1.41. Neurogene financial statements analysis is a perfect complement when working with Neurogene Valuation or Volatility modules.
Neurogene | Operating Cycle | Build AI portfolio with Neurogene Stock |
Analyzing Neurogene's Operating Cycle over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Operating Cycle has evolved provides context for assessing Neurogene's current valuation and future prospects.
Latest Neurogene's Operating Cycle Growth Pattern
Below is the plot of the Operating Cycle of Neurogene over the last few years. It is Neurogene's Operating Cycle historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurogene's overall financial position and show how it may be relating to other accounts over time.
| Operating Cycle | 10 Years Trend |
|
Operating Cycle |
| Timeline |
Neurogene Operating Cycle Regression Statistics
| Arithmetic Mean | 84.54 | |
| Geometric Mean | 36.63 | |
| Coefficient Of Variation | 128.66 | |
| Mean Deviation | 96.02 | |
| Median | 16.52 | |
| Standard Deviation | 108.76 | |
| Sample Variance | 11,830 | |
| Range | 239 | |
| R-Value | 0.78 | |
| Mean Square Error | 4,876 | |
| R-Squared | 0.61 | |
| Significance | 0.0002 | |
| Slope | 16.87 | |
| Total Sum of Squares | 189,277 |
Neurogene Operating Cycle History
About Neurogene Financial Statements
Neurogene stakeholders use historical fundamental indicators, such as Neurogene's Operating Cycle, to determine how well the company is positioned to perform in the future. Although Neurogene investors may analyze each financial statement separately, they are all interrelated. For example, changes in Neurogene's assets and liabilities are reflected in the revenues and expenses on Neurogene's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Neurogene. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Operating Cycle | 230.13 | 241.63 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Neurogene is a strong investment it is important to analyze Neurogene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neurogene's future performance. For an informed investment choice regarding Neurogene Stock, refer to the following important reports:Check out the analysis of Neurogene Correlation against competitors. For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Will Biotechnology sector continue expanding? Could Neurogene diversify its offerings? Factors like these will boost the valuation of Neurogene. Anticipated expansion of Neurogene directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Neurogene data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Understanding Neurogene requires distinguishing between market price and book value, where the latter reflects Neurogene's accounting equity. The concept of intrinsic value - what Neurogene's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Neurogene's price substantially above or below its fundamental value.
It's important to distinguish between Neurogene's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Neurogene should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Neurogene's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.